INS and early-onset autosomal dominant Alzheimer disease: Clinical trials for treating Alzheimer’s disease with insulin nasal spray20 and autism spectrum disorders with oxytocin nasal spray21 have reported that small molecule peptides delivered to the central nervous system by i.n. administration improved cognitive function and social behavior, respectively.